復星醫藥(02196.HK)與真實生物就新冠病毒及愛滋等達成戰略合作
復星醫藥(02196.HK)(600196.SH)公布,附屬公司復星醫藥產業與第三方真實生物訂立戰略合作協議;雙方就推進聯合開發並由復星醫藥產業獨家商業化阿茲夫定等事宜達成戰略合作。
合作領域包括新型冠狀病毒、愛滋病治療及預防領域;擬合作區域為內地(不包括香港、澳門及台灣地區),及除俄羅斯、烏克蘭、巴西及其他南美洲國家和地區外的全球其他地區。
雙方將聯合開發合作產品;及復星醫藥產業享有合作產品的獨家商業化權利,商業化包括經銷、進口、出口、銷售、推廣等行為。公司認為如該等合作依約開展,將有利於進一步豐富集團抗病毒產品線,滿足一線臨床用藥需求,並助力疫情防控。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.